TY - JOUR
T1 - Use of oxycodone controlled-release immediately after NSAIDs
T2 - A new approach to obtain good pain control
AU - Tessaro, Leopoldo
AU - Bandieri, E.
AU - Costa, G.
AU - Fornasier, G.
AU - Iorno, V.
AU - Pizza, C.
AU - Pastacaldi, G.
AU - Micheletto, G.
PY - 2010/2
Y1 - 2010/2
N2 - Introduction: Opioids are recommended as appropriate therapy for the treatment of cancer pain and chronic non-malignant pain. Oxycodone is an alternative agent to its parent compound, morphine, and is available in a controlled-release (CR) formulation that allows convenient twice-daily dosing. The aim of this study was to evaluate the efficacy and tolerability of oxycodone CR as first-line therapy in patients with chronic cancer or non-cancer pain that was not relieved by non-steroidal anti-inflammatory drugs (NSAIDs). Methods: This was a prospective, open-label, multicentre trial carried out in 8 pain and oncology centres in Italy. Patients (n=309) with NSAID-refractory chronic cancer (55.7%), non-cancer (39.4%) or mixed (4.9%) pain (rating of 4-10 on a numerical rating scale [NRS] from 0-10) were enrolled. Patients were treated with oral oxycodone CR twice daily for at least 28 days. Dosage was individualized for each patient and up-titrated over the first week of treatment. The primary endpoint was reduction in NRS score for pain. Secondary endpoints were tolerability, quality of life and patient assessment of treatment efficacy. Results: A significant decrease (57%) in pain intensity was recorded during the first week of therapy (decrease in NRS score from 7.85 ± 1.4 to 3.35 ± 1.8; p
AB - Introduction: Opioids are recommended as appropriate therapy for the treatment of cancer pain and chronic non-malignant pain. Oxycodone is an alternative agent to its parent compound, morphine, and is available in a controlled-release (CR) formulation that allows convenient twice-daily dosing. The aim of this study was to evaluate the efficacy and tolerability of oxycodone CR as first-line therapy in patients with chronic cancer or non-cancer pain that was not relieved by non-steroidal anti-inflammatory drugs (NSAIDs). Methods: This was a prospective, open-label, multicentre trial carried out in 8 pain and oncology centres in Italy. Patients (n=309) with NSAID-refractory chronic cancer (55.7%), non-cancer (39.4%) or mixed (4.9%) pain (rating of 4-10 on a numerical rating scale [NRS] from 0-10) were enrolled. Patients were treated with oral oxycodone CR twice daily for at least 28 days. Dosage was individualized for each patient and up-titrated over the first week of treatment. The primary endpoint was reduction in NRS score for pain. Secondary endpoints were tolerability, quality of life and patient assessment of treatment efficacy. Results: A significant decrease (57%) in pain intensity was recorded during the first week of therapy (decrease in NRS score from 7.85 ± 1.4 to 3.35 ± 1.8; p
KW - Analgesia
KW - Cancer pain
KW - Chronic pain
KW - NSAID-refractory pain
KW - Oxycodone controlled release (CR)
UR - http://www.scopus.com/inward/record.url?scp=77949630171&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77949630171&partnerID=8YFLogxK
M3 - Article
C2 - 20329570
AN - SCOPUS:77949630171
VL - 14
SP - 113
EP - 121
JO - European Review for Medical and Pharmacological Sciences
JF - European Review for Medical and Pharmacological Sciences
SN - 1128-3602
IS - 2
ER -